2021 Year in Review - HER2-Negative Breast Cancer

PARP inhibitors and immune checkpoint inhibitors have changed the breast cancer landscape, with trials that show improved progression-free survival and overall survival.
Improved knowledge of the biologic pathways, along with a number of new targeted therapies, has resulted in better outcomes for patients with HR-positive, HER2-negative breast cancer. These new therapies have been used in combination with older treatments to optimize patient outcomes.
CDK4/6 inhibitors in combination with antiestrogen therapy are the standard of care for HR-positive, HER2-negative advanced breast cancer. However, a diverse landscape of resistance to these therapies exists, which has resulted in precision-guided therapeutic strategies that are under active clinical development.
Olaparib monotherapy has shown promising clinical results in treatment-naïve TNBC with germline or somatic homologous repair deficiency, with fewer adverse events compared with traditional chemotherapy.
The COVID-19 pandemic continues to impact healthcare across the globe.
Dalpiciclib plus fulvestrant has been clinically demonstrated to significantly improve progression-free survival and reduce the risk for disease progression or death.
Despite their frailty and comorbidities in the elderly patient population, palbociclib was proven to be a well-tolerated treatment in elderly patients with advanced, ER-positive, HER2-negative breast cancer.
A completion of local treatment and neoadjuvant or adjuvant chemotherapy results in significantly longer survival, free of invasive or distant disease than placebo in patients with high-risk, HER2-negative early breast cancer, with germline BRCA1 or BRCA2 pathogenic variants.
Earlier this year, the independent data monitoring committee concluded that the OlympiA trial crossed the superiority boundary for its primary end point of invasive disease-free survival and demonstrated a sustainable, clinically relevant treatment effect for olaparib versus placebo in patients with germline BRCA mutation–positive, high-risk, HER2-negative, early breast cancer.
Patients with HR-positive, HER2-negative metastatic breast cancer are more likely to have disease response to palbociclib plus letrozole versus letrozole alone, according to a real-world study. However, in real-world practice, there is less information on the tumor response of palbociclib plus an aromatase inhibitor versus an aromatase inhibitor alone.
Page 2 of 3
Results 11 - 20 of 28

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country